{"preliminary_commentary":{"by_channel":{"x_thread":9,"youtube":7,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06520345\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"ProstACT Global","nct_id":"NCT06520345","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prostact-global-nct06520345. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Lutetium (177Lu) rosopatamab tetraxetan (177Lu-TLX591) 76 mCi (±10%) given approximately 14 days apart, plus SOC.\n\nSOC is either:\n\nConcurrent enzalutamide (starting dose 160 mg daily) + prednisone / prednisolone (5 mg twice a day) or equivalent.\n\nor\n\nConcurrent abiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (5 mg once daily for the standard formulation), methylprednisolone (4 mg twice daily for the fine particle formulation) or dexamethasone (1 mg once daily)\n\nor\n\nSequential Docetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone (5mg twice a day) or equivalent for up to 10 cycles.","label":"177Lu-TLX591 + Enzalutamide or Abiraterone or Docetaxel","type":"EXPERIMENTAL"},{"description":"SOC is either:\n\nEnzalutamide (starting dose 160 mg daily).\n\nor\n\nAbiraterone (starting dose 1,000 mg daily) + prednisone / prednisolone (up to 10 mg once daily for the standard formulation)\n\nor\n\nDocetaxel: Single agent chemotherapy will consist of docetaxel given at a recommended dose of 75mg/m2 IV every 3 weeks given in combination with oral prednisone / prednisolone 5mg twice a day (or equivalent) for up to 10 cycles","label":"Control Arm (Enzalutamide or Abiraterone or Docetaxel)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-12","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":520,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"177Lu-TLX591","otherNames":["Lutetium (177Lu) rosopatamab tetraxetan"],"type":"DRUG"},{"name":"Enzalutamide","otherNames":[],"type":"DRUG"},{"name":"Abiraterone","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-07-21","lead_sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","official_title":"A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination With Standard of Care Versus Standard of Care Alone in Patients With PSMA Positive Metastatic Castration-Resistant Prostate Cancer Previously After Androgen Receptor Pathway Inhibitor Treatment","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-12","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Radiographic Progression-free Survival","timeFrame":"337days"}],"references":[],"start_date":{"date":"2024-07-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","url":"https://clinicaltrials.gov/study/NCT06520345"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prostact-global-nct06520345"}